antiarrhythmics
in review
5 min read
Updated 2026-10-19
antiarrhythmics
Choice is set by the substrate, not the arrhythmia: structurally normal heart → flecainide/propafenone (always with an AV-nodal blocker), dronedarone, sotalol; CAD → no class Ic; HFrEF → amiodarone only. Every AAD can be proarrhythmic, and none replaces anticoagulation. Rate-control drugs → atrial fibrillation.
comparison
| Drug | Class / action | Oral maintenance | Avoid if | Monitor |
|---|---|---|---|---|
| flecainide | Ic — use-dependent Na⁺ block | 50–150 mg BID | CAD/prior MI, LVEF ≤40%, significant LVH, LBBB or RBBB + hemiblock, 2nd/3rd-degree AVB, CrCl <35, severe liver disease, Brugada | ECG at baseline and after start: stop if QRS widens >25% |
| propafenone | Ic + weak β-block | 150–300 mg TID | as flecainide | as flecainide |
| sotalol | III (IKr) + β-block | 80–160 mg BID | QTc prolongation, LVEF ≤40%, CrCl <40 (adjust 40–60), high-grade AVB, older women on diuretics | QTc at baseline and 48–72 h (start in a monitored setting). VT dosing 40–80 → 120–160 mg BID; avoid GFR <30 |
| dronedarone | multichannel, amiodarone analogue without iodine | 400 mg BID | permanent AF, LVEF ≤40% or recent decompensated HF, high-grade AVB, QTc prolongation, prior amiodarone lung/liver toxicity, severe liver disease | LFTs q3 mo × 1 year, then q6 mo |
| amiodarone | multichannel (I–IV) | AF: load 10–12 g total (CCS; ACC/AHA 6–10 g), then ≤200 mg daily. VT: 400 mg BID × 14 days, then 200–400 mg daily | high-grade AVB, liver disease, interstitial lung disease, QTc prolongation, iodine allergy, strong CYP3A4 inhibitors | TSH and LFTs q6 mo, annual CXR, vision symptoms |
- Class Ic + AV-nodal blocker always (beta-blocker, diltiazem or verapamil): Ic slows atrial flutter to ~200/min → 1:1 conduction → very fast wide-complex rhythm
- Before class Ic: exclude ischaemia (stress test if >50 y or atherosclerotic risk factors); reassess for CAD symptoms yearly
- Amiodarone last for AF rhythm control — only when other options are contraindicated or failed (CCS strong); exception: HFrEF, where amiodarone is the main option (ESC I; ACC/AHA amiodarone or dofetilide)
- Dronedarone: not for rate control or in HF (CCS strong); the only AAD shown to ↓ CV hospitalisation/death (paroxysmal/persistent AF with risk factors)
- No AAD in advanced sinus/AV node disease without a pacemaker. Stop AADs once AF is accepted as permanent
acute IV use
| Drug | Use | Dose | Key cautions |
|---|---|---|---|
| procainamide | recent-onset AF (most-used ED agent in Canada); stable monomorphic VT; pre-excited AF | AF: 1 g over 60 min. VT: 10 mg/kg over 20 min, then 1–2 mg/min | hypotension, QRS widening, Brugada |
| ibutilide | AF/flutter cardioversion (more effective for flutter); pre-excited AF | 1 mg over 10 min (0.01 mg/kg if <60 kg); Mg²⁺ before | TdP 2–3% (ACC/AHA up to 7%) → avoid QTc >440, HF/low EF, low K⁺/Mg²⁺; monitor ≥4 h |
| vernakalant | recent-onset AF | 3 mg/kg over 10 min (max 339 mg); second dose 2 mg/kg | hypotension, NYHA III–IV HF, bradycardia, recent ACS, severe AS |
| amiodarone | VT/VF arrest; stable VT; AF with HFrEF/hypotension | arrest: 300 mg IV push, then 150 mg. Stable VT: 150 mg over 10 min → 1 mg/min × 6 h → 0.5 mg/min × 18 h | hypotension, phlebitis; delayed AF conversion (8–12 h); never in pre-excited AF |
| lidocaine | shock-refractory VT/VF; ischaemic VT | arrest: 100 mg IV push, then 50 mg. Stable VT: 1 mg/kg → 1–2 mg/min | CNS toxicity, seizures |
- Pill-in-the-pocket: flecainide 200–300 mg or propafenone 450–600 mg PO at onset, plus an AV-nodal blocker. First dose in a monitored setting; for infrequent, symptomatic episodes in a structurally normal heart
- Electrical storm (≥3 VT/VF episodes in 24 h) with structural heart disease → IV amiodarone + beta-blocker (preferably non-selective, e.g. propranolol); keep K⁺ ≥4.0 and Mg²⁺ ≥0.9–1.0 → ventricular arrhythmias and sudden cardiac death
- Prophylactic lidocaine or amiodarone after MI ↑ harm — not used
key points
- Mortality signals drive the rules: flecainide/encainide ↑ death after MI in CAST (1991) → no Ic with CAD. Dronedarone ↑ death in severe HF (ANDROMEDA (2008)) and permanent AF (PALLAS (2011)), but ↓ CV hospitalisation/death in paroxysmal or persistent AF with risk factors (ATHENA (2009))
- Sotalol: β-block at low doses, class III at higher doses; reverse use-dependent → QT effect greatest at slow rates
- Amiodarone interactions: inhibits CYP3A4, CYP2C9 and P-gp → INR rises on warfarin, digoxin levels rise, statin toxicity → reduce doses and monitor. Long half-life → interactions persist for weeks after stopping
- Dronedarone is a P-gp/CYP3A4 inhibitor → ↑ DOAC and digoxin levels; simvastatin ≤10 mg
- Pre-excited AF: procainamide or ibutilide (slow the pathway); IV amiodarone, digoxin, diltiazem, verapamil and beta-blockers are not recommended (potentially harmful); oral digoxin also harmful long term
adverse effects
| Drug | What matters |
|---|---|
| amiodarone | pulmonary fibrosis (persistent dry cough), thyroid (hypo- or hyperthyroidism), hepatitis, optic neuropathy, photosensitivity/blue-grey skin, bradycardia; QT prolongation but TdP is uncommon |
| dronedarone | hepatotoxicity, HF worsening, QT prolongation |
| sotalol | TdP (dose and renal function related), bradycardia, bronchospasm |
| flecainide / propafenone | 1:1 flutter, VT in structural heart disease, QRS widening; propafenone bronchospasm (β-blocking) |
| procainamide | hypotension; drug-induced lupus with chronic use |
Prepared 2026-10-19. Not yet verified — check every number against the sources.